<DOC>
	<DOCNO>NCT02305927</DOCNO>
	<brief_summary>The purpose study assess effect maternal vitamin D3 ( cholecalciferol ) supplementation maternal HIV progression , small-for-gestational age infant , infant stunt 12 month postpartum HIV-infected Tanzanian pregnant woman receive highly active antiretroviral therapy ( HAART ) .</brief_summary>
	<brief_title>Trial Vitamin D HIV Progression , Birth Outcomes , Child Health</brief_title>
	<detailed_description>The study randomize , double-blind , placebo-controlled trial maternal vitamin D3 ( cholecalciferol ) supplementation start second trimester ( 12-27 week gestation ) continue 12 month postpartum among HIV-infected Tanzanian pregnant woman receive HAART . Eligible individual randomize receive ) vitamin D3 regimen consist 3,000 IU vitamin D3 take orally daily start second trimester continue 12 month postpartum b ) placebo regimen take orally daily start second trimester continue 12 month postpartum . Mothers follow study visit pregnancy mother/infant pair attend study visit birth trial discharge 12 month postpartum .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Women age ≥18 year old HIVpositive Receiving HAART Pregnant 1227 week gestation ( Second Trimester ) Calcium level normal physiologic range ( ≤2.6 mmol/L ) Enrolled clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Pregnant woman</keyword>
</DOC>